Hashimoto Takeshi, Yoshioka Kunihiko, Gondo Tatsuo, Ozu Choichiro, Horiguchi Yutaka, Namiki Kazunori, Ohno Yoshio, Ohori Makoto, Nakashima Jun, Tachibana Masaaki
Department of Urology, Tokyo Medical University Hospital, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan,
Int J Clin Oncol. 2014 Aug;19(4):702-7. doi: 10.1007/s10147-013-0611-0. Epub 2013 Sep 19.
We investigated oncological outcomes in Japanese patients who underwent robot-assisted radical prostatectomy (RARP).
This study included 389 patients who underwent RARP at a single institution with a follow-up period of at least 1 year. Preoperative findings were compared with biochemical recurrence (BCR). Predictors of BCR-free survival (BCRFS) were evaluated by univariate and multivariate Cox proportional hazard model analyses, and a risk stratification model based on the relative risks of BCR was established.
Fifty incidences of BCR were noted during a median follow-up period of 28.7 months (range, 12.1-80.0 months). The BCRFS rate for the entire cohort at the median follow-up time was 85.9 %; the 1-, 3-, and 5-year estimates were 91.0, 85.1, and 81.1 %, respectively. From univariate analyses, prostate-specific antigen (PSA), PSA density, biopsy Gleason score, and percent positive core were significantly associated with BCR. Multivariate analysis showed that PSA [hazard ratio (HR), 2.75; p = 0.001], percent positive core (HR, 2.22; p = 0.001), and biopsy Gleason score (HR, 2.61; p = 0.007) were independent predictors of BCR.
This study at a single Japanese center demonstrates that RARP provides a satisfactory BCRFS rate. This report provides a framework with which to estimate oncological outcomes in patients who underwent RARP for localized prostate cancer. Our results support the increased use of RARP for the treatment of localized prostate cancer in Japan.
我们调查了接受机器人辅助根治性前列腺切除术(RARP)的日本患者的肿瘤学结局。
本研究纳入了389例在单一机构接受RARP且随访期至少1年的患者。将术前检查结果与生化复发(BCR)进行比较。通过单因素和多因素Cox比例风险模型分析评估无BCR生存(BCRFS)的预测因素,并建立基于BCR相对风险的风险分层模型。
在中位随访期28.7个月(范围12.1 - 80.0个月)内记录到50例BCR事件。整个队列在中位随访时间的BCRFS率为85.9%;1年、3年和5年的估计值分别为91.0%、85.1%和81.1%。单因素分析显示,前列腺特异性抗原(PSA)、PSA密度、活检Gleason评分和阳性核心百分比与BCR显著相关。多因素分析表明,PSA[风险比(HR),2.75;p = 0.001]、阳性核心百分比(HR,2.22;p = 0.001)和活检Gleason评分(HR,2.61;p = 0.007)是BCR的独立预测因素。
在日本单一中心进行的这项研究表明,RARP能提供令人满意的BCRFS率。本报告提供了一个框架,用于估计接受RARP治疗局限性前列腺癌患者的肿瘤学结局。我们的结果支持在日本增加使用RARP治疗局限性前列腺癌。